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Fifteen years of experience 
with mechanical prostheses 
and bioprostheses 
Tricuspid valve replacement is not a common operation. The purpose of this study 
was to examine the early and late results in 60 patients who underwent 28 (417%) 
bioprosthetic and 32 (53%) mechanical tricuspid valve replacements. All operations 
took place between January 1978 and June 1993 during which period a total of 4741 
patients underwent valve replacement operation. Mean patient age was 50 - 15 (18 
to 75) years. Forty-one patients (68%) were female and 19 patients (32%) were male. 
Forty-nine patients (82%) were in New York Heart Association class I I I  or IV before 
operation. Forty-five patients (75%) were undergoing repeat cardiac valve operation. 
Seventeen patients (28%) had complex congenital cardiac problems. Operation was 
urgent in 15 patients (25%). The hospital mortality rate was 27% (16 patients). All 
patients with hospital death were in New York Heart Association class I I I  or IV, ,were 
having repeat operations, or had complex congenital disease. Low output syndrome 
was observed in 21 patients (35%). Reoperation because of bleeding was required in 
seven patients (12%). Thirteen patients (22%) required permanent (epicardial lead) 
pacemaker implantation. Mean follow-up is 75 - 45 months (maximum 173 
months) and 100% complete for the 44 patients who left the hospital. There have 
been 14 deaths (32%). Nine of these patients (64%) had mechanical valves and five 
(36%) had bioprostheses. Of the 11 cardiac deaths, three were valve related 
(bioprostheses). Three patients (10%) required reoperation because of tricuspid 
valve prosthetic failure (1 thrombosed mechanical valve, 2 failed porcine valves). Of 
the remaining 30 patients, 20 (67%) are in New York Heart Association class I or II. 
Seventeen patients have mechanical valves and 13 have bioprostheses. Twenty-six 
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patients (90%) are receiving warfarin. Thromboembolism (transient ischemic 
attack) has occurred in one patient with a mechanical valve who also had a previous 
cerebrovascular accident. In this group there has been no hemorrhage, endocarditis, 
or new pacemaker equirement. Actuarial survival for the whole series is 37% _+ 9% 
and for the hospital survivors is 50% -+ 12% at 15 years. Linearized rates of 
valve-related complications are not different between groups. Tricuspid valve 
replacement is a beneficial procedure for patients with structural tricuspid valve 
disease, many of whom have other valvular or congenital disease. Contemporary 
mechanical prostheses and bioprostheses are equally effective in the tricuspid 
position. Mechanical valves should be considered for tricuspid replacement in young 
patients and in patients with mechanical valves implanted in the left side of the 
heart. (J T~IORAC CARDIOVASC SURG 1995;109:1035-41) 
R eplacement of diseased cardiac valves with ei- ther mechanical or biologic tissue prostheses has 
become an established therapeutic procedure since 
the first aortic and first mitral implants were done by 
Harken 1 and Braunwald 2 and their associates in 
1960. Many model changes and refinements have 
been made, and much discussion of the relative 
merits of different types of heart valves has en- 
sued.3, 4
Tricuspid valve surgery has always been a chal- 
lenging problem, whether in isolation or in combi- 
nation with the surgical approach to other valve or 
congenital abnormalities. 543 When a decision is 
made to replace the tricuspid valve, the choice of 
prosthesis remains controversial. The lower pres- 
sures and flows in the right side of the heart 
predispose mechanical prostheses to a high rate of 
valve thrombosis, 14-17 although design improve- 
ments in contemporary mechanical prostheses ap- 
pear to have ameliorated this problem significant- 
ly. 1s-24 The rate of degeneration of bioprostheses in 
the tricuspid position has been observed to be 
appreciably slower than the rate for biological valves 
placed on the systemic side of the circulationy' 2s-29 
but calcification does result in late dysfunction. 25-3° 
The purpose of this review was to examine our 
experience with tricuspid valve replacement during 
the past 15 years and to compare and contrast early 
and late results in patients who had received either 
contemporary mechanical prostheses or biopros- 
thetic heart valves. 
Methods 
Between January 1978 and June 1993, 4741 patients 
underwent valve replacement a The Toronto Hospital. 
Sixty patients (1.3%) required tricuspid valve replacement 
(Table I). Twenty-eight (47%) biologic valves and 32 
(53%) mechanical valves were implanted. Patient demo- 
graphics are presented in Table II. For 38 patients (63%) 
this was a first-time tricuspid valve operation. Complex 
congenital problems involving the right side of the heart 
and the tricuspid valve were present in 17 patients (28%). 
Forty-five patients (75%) had undergone a cardiac oper- 
ation at least once before (Table III). Eight of these 
patients had undergone tricuspid valve repairs that had 
failed. Fourteen patients had had failure of tricuspid 
prostheses. Eleven of the failures were of mechanical 
valves: eight Starr-Edwards* ball cage prostheses (ball 
entrapment, prosthetic stenosis), two spherical disc Bj6rk- 
Shileyt valves (valve thrombosis), and one Beall~ model 
104 floating disc prosthesis (valve thrombosis and disc 
wear). Three were of porcine valves that had failed after 9, 
13, and 14 years of implantation, respectively. The tricus- 
pid valve abnormality encountered at the time of tricuspid 
valve replacement is shown in Table IV. Tricuspid insuf- 
ficiency treated conservatively (nonoperatively) at initial 
mitral or mitral and aortic valve operation, or as a 
consequence of failed annuloplasty orrepair, or both, at a 
previous operation, was present in 14 patients. The prev- 
alent congenital disease was Ebstein's malformation. Two 
of the patients with endocarditis abused intravenous 
drugs. In one of the patients in the "trauma" category the 
tricuspid valve had "burst" in a motor vehicle accident. 
The other trauma case was iatrogenic and involved irrep- 
arable damage to the tricuspid valve during a repeat 
operation for a recurrent or residual left atrial myxoma. 
The range of operations done on these 60 patients is 
presented inTable V. Sixteen of the 21 patients undergo- 
ing isolated tricuspid valve replacement had undergone a 
previous cardiac operation. Concomitant procedures at 
this operation were done in 39 patients (65%). 
All patients underwent median sternotomy or rester- 
notomy. Intraoperative myocardial protection was pro- 
vided by moderate hemodilution, systemic hypothermia to
28 ° to 32 ° C, and cold crystalloid potassium-rich ardiople- 
gic solution (before 1984) or cold blood cardioplegic 
solution (after 1984) infused in an antegrade fashion 
under pressure either into the aortic root (mitral or 
*Baxter Healthcare Corp., Edwards Division, Santa Ana, Calif. 
tShiley Inc., Irvine, Calif. 
:~Surgitool, Inc., Pittsburgh, Pa. 
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Table I. Tricuspid valve replacement by type and 
model (total of 60 patients: 1.3% of 4741) 
No. % 
Biologic (n = 28, 47%) 
Hancock II porcine* 14 50.0 
Carpentier-Edwards porcine? 8 28.6 
Ionescu-Shiley pericardial~ 3 10.7 
Medtronic Intact§ 2 7.1 
Hancock pericardial 1 3.6 
Mechanical (n = 32, 53%) 
Bj6rk-Shiley Monostrut:~ 23 71.9 
Bi6rk-Shiley welded outlet 5 15.6 
strut, 60- and 70-degree~ 
St. Jude Medical bileaflet# 4 12.5 
*Johnson & Johnson Cardiovascular, King of Prussia, Pa. 
tBaxter Healthcare Corp., Edwards Division, Santa Ana, Calif. 
:~Shiley, Inc., Irvine, Calif. 
§Medtronic, Inc., Minneapolis, Minn. 
#St. Jude Medical, Inc., St. Paul, Minn. 
Table II. Patient demographics 
No. % 
Mean age (yr): 50 + 15 (18-75) 
Sex 
Female 41 68 
Male 19 32 
Repeat operation 45 75 
Urgent operation 15 25 
NYHA class III and IV 49 82 
tricuspid valve operation or operation for congenital 
disease) or directly into the coronary ostia (aortic valve 
operation). All valves were secured in position by an 
interrupted horizontal mattress uture technique rein- 
forced by Teflon felt pledgets placed on the ventricular 
aspect of the valve anulus. 
Statistical analysis. Actuarial analysis was done by 
life-table methods, and linearized rates of valve-related 
complications were calculated for each type of prosthesis. 
Actuarial survival including hospital mortality was calcu- 
lated for the 60 original patients and for the 44 hospital 
survivors, with analysis of each type of prosthesis. The 
generalized Wilcoxon and Mantel-Haenszel tests were 
used to examine differences in actuarial rates. Continuous 
data are presented as mean plus or minus the standard 
deviation. The number of patients in this study was not 
sufficient o allow for meaningful calculation ofp values. 
Results 
Hospital results. The hospital mortality and mor- 
bidity were not significantly different between the 
patients undergoing biologic tricuspid valve replace- 
ment and those in whom mechanical valves were 
implanted (Table VI). The hospital mortality rate 
was 27% (16 patients). All 16 of these patients were 
Table III. Previous cardiac operations: 45 patients 
(75%) 
No. % 
Tricuspid operation 
Repair 8 17.8 
Replacement 14 31.1 
Mitral operation 
Repair (closed/open) 10 22.2 
Replacement 23 51.1 
Aortic valve operation 
Replacement 10 22.2 
Congenital defect repair 9 20.0 
Aorta-coronary b pass 3 6.7 
Table IV. Tricuspid valve disease or injury 
No. % 
Rheumatic tricuspid stenosis 22 36.7 
Congenital 17 28.3 
Tricuspid insufficiency 14 23.3 
Failed tricuspid prosthesis 14 23.3 
Failed tricuspid repair 8 13.3 
Endocarditis 5 8.3 
Trauma 2 3.3 
in New York Heart  Association (NYHA) functional 
class I I I  or IV. Five patients underwent triple valve 
replacement. Four of the five patients undergoing 
isolated tricuspid replacement also had concomitant 
cardiac procedures. Twelve of the 16 patients who died 
in the hospital had undergone previous cardiac oper- 
ations, as had all 7 patients who required reoperation 
because of bleeding. Of the 21 patients (35%) who had 
low output syndrome, all had undergone repeat oper- 
ation, combined procedures, or both. 
Late results. Follow-up through a constantly up- 
dated Valve Patient Registry at The Toronto Hos- 
pital that uses personal interviews and assessments, 
telephone contact, and review of hospital and phy- 
sician patient records is 100% complete for the 44 
patients discharged from the hospital. The mean 
follow-up interval was 75 + 45 months (maximum 
173 months). The causes of the 14 late deaths are: 
presented in Table VII. Three patients died of 
malignancy or accident or other disease unrelated to 
the valve or to the heart. Eight patients died of 
cardiac causes unrelated to the implanted valve:: 
progressive myocardial failure (6), ischemic heart 
disease (1), and, in one patient, pulmonary edema 
caused by catastrophic failure of a mitral Ionescu-- 
Shiley* bovine pericardial prosthesis 63 months 
*Shiley, Inc., Irvine, Calif. 
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Table V. Operations performed 
Biologic Mechanical 
(n =28, (n =32, 
47%) 53%) 
No. % No. % 
Isolated TVR 7 25.0 14 43.8 
Concomitant procedures 
MVR + TVR 7 25.0 7 21.9 
AVR + MVR + TVR 5 17.8 6 18.8 
Congenital defect repair + TVR 7 25.0 3 9.4 
MV repair + TVR 1 3.6 1 3.1 
AVR + TVR (endocarditis) 1 3.6 0 
Aorta-coronary operation 0 1 3.1 
(+AVR, MVR, TVR) 
TVR, Tricuspid valve replacement; MVR, mitral valve replacement; AVR, 
aortic valve replacement; MV,, mitral valve. 
Table VI. Hospital results 
Biologic Mechanical 
(n =28, (n =32, 
47%) 53%) 
No. % No. % 
Mortality 9 31.2 7 21.9 
Morbidity 
Low output syndrome 9 31.2 12 37.5 
Reoperation because of bleeding 4 14.3 3 9.4 
Permanent pacemaker 7 25.0 6 18.8 
Deep sternal infection 1, 3.6 0 
Cerebrovascular accident 1 3.6 0 
after implantation (at autopsy the tricuspid bovine 
pericardial valve was structurally and functionally 
intact). 
There were three valve-related eaths, all in 
patients with bioprostheses. One patient who 
abused intravenous drugs died of recurrent endocar- 
ditis. One patient with poorly controlled warfarin 
(Coumadin) anticoagulation died of cerebrovascu- 
lar hemorrhage. One patient whose porcine tricus- 
pid valve failed in the tenth year after implantation 
died at third-time tricuspid valve replacement. The 
complications that occurred in the 44 hospital sur- 
vivors are presented inTable VIII. Structural failure 
occurred in two of the tricuspid bioprosthetic valves 
implanted in 19 hospital survivors. The patient 
noted earlier, whose tricuspid valve failed in the 
tenth year (112 months), also had a failing mitral 
porcine valve. The other patient, whose porcine 
tricuspid valve failed in the fifteenth implant year 
(171 months), had a coexisting porcine mitral valve. 
This patient remains well after ereplacement wi h a 
Table VII. Late results: mortality (N = 14/44, 32%) 
Biologic Mechanical 
(n =19) (n =25) 
Cause of death No. % No. % 
Valve related 3 15.8 0 
Cardiac (nonvalve) 1 5.3 7 28.0 
Other 1 5.3 2 8.0 
Table VIII. Late results: complications 
Biologic Mechanical 
(n=19) (n=25) 
Linearized rate 
No. % No. % (%/100 pt-yr) 
Structural failure 2 10.5 0 0.73 
Thrombosis/thrombo- 0 2 8.0 0.73 
embolism 
Anticoagulant-related 1 5.3 0 0.36 
hemorrhage 
Prosthetic valve en- 1 5.3 0 0,36 
docarditis 
CarboMedics* valve. None of the mechanical valves 
failed structurally, including the five convexo-con- 
cave disc 60- or 70-degree Bj6rk-Shiley valves "at 
risk" with welded outlet struts. None of the 28 
patients till alive who are receiving life-long warfa- 
rin anticoagulant therapy have had any significant 
anticoagulant-related h morrhage. Warfarin dosage 
is monitored with use of the international normal- 
ized ratio. Twenty (67%) of the 30 patients till alive 
are in NYHA functional class I or II. Subjectively 
80% of patients feel better than they did before the 
operation. Actuarial survival for the entire group of 
60 patients is 37% _+ 9% at 15 years (Fig. 1), and 
actuarial survival of the 44 hospital survivors is 
50% -+ 12% (Fig. 2). Linearized rates of valve- 
related complications were not different between 
the two types of valves implanted (Table VIII). 
Discussion 
In recent years, as in this series, tricuspid valve 
replacement is uncommon. 5' 8, 10,11, 22 It is generally 
agreed that tricuspid annuloplasty is the preferred 
treatment for moderate to severe tricuspid insuffi- 
ciency. Tricuspid valve replacement is usually re- 
served for those patients with significant organic 
tricuspid valve disease that is unlikely to improve if 
more conservative measures are taken. 5-13 
*CarboMedics, Inc., Austin, Tex. 
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The hospital mortality rate has been reported to 
be between 10% and 54%. 7, 8, 10q2, 22, 26 The hospi- 
tal mortality rate of 27% in this series was higher 
than some, but is consistent with the reality that 
most of these patients were undergoing complex 
repeat operations. In a comparison of the hospital 
mortality and postoperative morbidity between pa- 
tients who were undergoing biologic or mechanical 
prosthetic tricuspid replacement, we found no dif- 
ference. Although others have noted a higher hos- 
pital mortality with the use of mechanical prosthe- 
ses,26, 2s other things being equal, it is logical that 
there would be no difference. There was no differ- 
ence in the early morbidity between the two groups 
of patients. Again, other things being equal, none 
would be expected. The late mortality of 14 patients 
(32%) in the series compares well with that of other 
reports]' 8, 22-24 All of the patients have been fol- 
lowed up closely with early adjustment of medica- 
tions as required. 
There was an apparent difference in the rates of 
late death between the nine patients with mechani-. 
cal tricuspid prostheses and the five patients with 
bioprostheses. However, the deaths in patients with 
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mechanical valves were not valve related. The three 
late valve-related eaths all occurred in patients 
with bioprosthetic valves, although one death as a 
result of cerebral hemorrhage was not related to the 
valve type but caused by poor warfarin control. By 
the mid-1970s there were reports of significant valve- 
related problems with valve thrombosis of (tilting) disc 
valves 15-17 or pannus formation and ball entrapment 
with ball-cage valves implanted in the tricuspid posi- 
tion.a, 14,16 By comparison there was relative freedom 
from degeneration r structural failure of bioprosthe- 
ses implanted in the right side of the heart. 22 Conven- 
tional wisdom was that a porcine bioprosthesis should 
be implanted when tricuspid valve replacement was 
indicated, regardless of the prostheses implanted in 
the left side of the heart. 22' 25-29 The lag in valve leaflet 
opening caused by lower flows to overcome valve 
inertia in the right side of the heart and the ultimate 
degeneration f the valves were considered reasonable 
risks by comparison. In the late 1970s there were 
reports of improved hemodynamics, less transpros- 
thetic stasis and turbulence in the redesigned isc, 
and new bileaflet valves with documented improve- 
ments in rates of valve thrombosis and thromboembo- 
lism.3,18-21, 23, 24 It seemed reasonable toagain implant 
contemporary mechanical prostheses in the tricuspid 
position, particularly in association with implantation 
of mechanical valves in the systemic irculation or in 
other circumstances in which the patients would re- 
quire life-long warfarin anticoagulation therapy. 
In this series there were two structural failures of 
porcine bioprostheses in the tricuspid position at 
intervals of 9 years and 14 years. Three of the 
original 60 patients required repeat ricuspid valve 
replacement because of porcine valve failure at 
similar intervals. As noted by others, s' 14, 16 these 
failures were delayed beyond what might have been 
expected in the left side of the heart. However, both 
patients required reoperation. One of these reop- 
erations was successful and involved failed tricuspid 
bioprosthetic replacement by a mechanical valve. One 
patient died: the mitral bioprosthesis had also failed at 
9 years and the third-time operation to replace both 
failed bioprostheses was not successful. One hospital 
survivor in whom bioprostheses had been implanted in 
both the mitral and tricuspid positions died as a 
consequence of catastrophic failure of the mitral bio- 
prosthesis. If contemporary mechanical prostheses had 
been used in these six patients who had structural 
bioprosthetic valve failure, it is likely that they would 
have continued to do well. 
On the other hand, one of the Monostrut Bj6rk- 
Shiley valves did develop thrombus to the extent 
that significant ricuspid prosthetic stenosis devel- 
oped. Thrombolytic treatment was successful in 
clearing lesser thrombus compromise of the coexist- 
ing mitral Monostrut Bj6rk-Shiley valve. The tricus- 
pid valve thrombus proved refractory, and the pros- 
thesis was successfully replaced. There was one 
transient ischemic attack in a patient with a mechan- 
ical valve. However, the patient was also in atrial 
fibrillation, had a history of preoperative mbolic 
cerebrovascular accident, and never manifested any 
evidence of pulmonary embolus. Valve type was 
likely irrelevant o this complication. 
In conclusion, the important finding of this study 
is that at 15 years there is no difference in patient 
survival or valve-related complications in patients in 
whom tricuspid valves have been replaced with 
either contemporary mechanical or bioprosthetic 
valves. There was a tendency to late failure in the 
bioprostheses and others may fail with the passage 
of time. Should this be the situation, it would add 
strength to the argument hat contemporary me- 
chanical valves should be used preferentially for 
tricuspid replacement in patients who can tolerate 
warfarin anticoagulation therapy. However, because 
tricuspid valve replacement represents such a small 
percentage ofvalve operations, it would be desirable 
to combine the results from several centers to 
produce sufficient numbers for good statistical anal- 
ysis. From the results of our study, we recommend 
consideration of implantation of contemporary me- 
chanical prostheses in the tricuspid position in 
younger patients, in patients in whom mechanical 
valves are also being implanted in the mitral or 
aortic position, and in patients who require life-long 
warfarin anticoagulation therapy. 
We thank Erluo Chen, MPH, for her assistance in the 
statistical nalysis of the data and Cathy Tong, HRA, and 
Suzanne Murphy for their patient assistance in prepara- 
tion of the manuscript. 
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Discussion 
Dr. Norberto G. De Vega (Mdlaga, Spain). I fully agree., 
with the authors' conclusions. In our experience, in the., 
past 14 years, out of more than 4000 valve operations, we', 
have had to replace the tricuspid valve on only 10 occa-. 
sions. In only one of those patients was the replacement 
done as a primary valve operation. We have always used a 
bileaflet valve, either a St. Jude Medical or, more recently, 
the new A.T.S. valve. Except for one patient in whom a 
partial thrombosis of the St. Jude Medical tricuspid valw ~, 
developed on two occasions, and resolved with thrombol- 
ysis, all patients are doing well. Therefore we agree that if 
a tricuspid valve has to be replaced, it is better to use a 
bileaflet valve than a bioprosthesis. 
Dr. Scully. Thank you, Dr. De Vega. We are now 
favoring mechanical valves rather than bioprostheses for 
tricuspid valve replacement. 
